NMI 8739

Research use only, not for human use.

NMI 8739 is an agonist of D2 autoreceptor. NMI 8739 reduces NO production and elicits concentration-dependent suppression of CCL-20, MCP-1 and IL-6 release.

NMI 8739 is an agonist of D2 autoreceptor. NMI 8739 reduces NO production and elicits concentration-dependent suppression of CCL-20, MCP-1 and IL-6 release.(In Vitro):NMI 8739 (2 μM) significantly inhibits IL-6 and CCL-20 release up to 49% and 37%, respectivel. NMI 8739 suppresses the production of PGE2 in a concentration-dependent manner with 25.3%, 75% reduction at doses of 100 nM and 1 μM, respectively.

NMI 8739 is a dopamine D2 autoreceptor agonist, which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine. NMI 8739 reduces nitric oxide (NO) production in LPS-stimulated RAW264.7 Macrophages. NMI 8739 elicits concentration-dependent suppression of CCL-20, MCP-1 and IL-6 Release in RAW264.7 macrophages after LPS-stimulation. Production of PGE2 is concentration-dependently suppressed with a reduction of 25.3% at 100 nM NMI 8739 and a 75% reduction for 1 μM NMI 8739. 2 μM NMI 8739 significantly inhibits IL-6 and CCL-20 release up to 49% and 37%, respectively.

——

Dha-DA conjugate | n-docosahexaenoyl dopamine

GPCR/G Protein

Dopamine Receptor

——

——

——

129024-87-9

463.662

C30H41NO3

>98% (HPLC)

In Vitro:?Ethanol : 100 mg/mL (215.68 m)

CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCc1ccc(O)c(O)c1

——

(-20℃)

With Ice Pack

≥ 2 years